Live Breaking News & Updates on Lutikizumab

Stay updated with breaking news from Lutikizumab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Raj Chovatiya, MD, PhD: Takeaways from New Data on Vitiligo, Atopic Dermatitis, HS Treatments

This post-AAD interview with Chovatiya covered takeaways regarding recent data on upadacitinib for vitiligo, tapinarof for eczema, and lutikizumab for hidradenitis suppurativa. ....

United States , San Diego , Raj Chovatiya , American Academy Of Dermatology , Immunology Research , Rosalind Franklin University Chicago Medical School , Medical Dermatology , Hidradenitis Suppurativa ,

Discussing New Phase 2 Findings on Lutikizumab for Hidradenitis Suppurativa with Alexa Kimball, MD, MPH

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.
....

United States , Alexa Kimball , Harvard Medical School , American Academy Of Dermatology , Annual Meeting , Hidradenitis Suppurativa Clinical Response , Massachusetts General Hospital , Numeric Rating Scale , Global Assessment , Hidradenitis Suppurativa , Anti Tnf , Phase 2 , Late Breaking ,

Martina J. Porter, MD: Adverse Events, Future Research on Lutikizumab for HS

In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.
....

Martinaj Porter , Harvard Medical School , Hidradenitis Suppurativa ,

Martina J. Porter, MD: Discussing New Findings on Lutikizumab for HS Patients

In this interview, Porter describes some new and encouraging phase 2 data on lutikizumab treatment for patients with HS who had failed anti-TNF therapy.
....

Martinaj Porter , Harvard Medical School , Beth Israel Deaconess Medical Center , Hidradenitis Suppurativa ,

Positive Response Observed in HS Patients Having Failed Anti-TNF Therapy Treated with Lutikizumab

These phase 2 data on hidradenitis suppurativa patients highlight new information on the use of lutikizumab as a treatment alternative. ....

Alexab Kimball , Roopal Thakkar , Harvard Medical School , Beth Israel Deaconess Medical Center , Numeric Rating Scale , Hidradenitis Suppurativa , Tnf Therapy ,